TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05711654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Coaching interview will be held with patients at regular intervals.
Study: NCT04077086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Intervention group children in middle school Year 1 will receive spectacles in December 2024. Assuming that the relevant effects of treatment (glasses wear) on the main study outcome are complete once examinations determining high school attendance are finished at the end of Middle School Year 3, Intervention participants will have undergone 32 months (December 2024 - July 2027) of treatment by the endpoint of the trial.
Study: NCT05445700

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia pump (PCA)
Description: Each patient will receive a PCA pump with intravenous (i.v.) morphine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia pump (PCA)
Description: Each patient will receive a PCA pump with intravenous (i.v.) morphine.
Study: NCT06509464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: High intensity interval training on treadmill

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caloric restricted diet
Description: Caloric restricted diet
Study: NCT05445700

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia pump (PCA)
Description: Each patient will receive a PCA pump with intravenous (i.v.) morphine.
Study: NCT05532241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fixed metal orthodontic appliance
Description: fixed metal orthodontic appliance (stainless steel brackets (Mini Master MBT 0.022'', American Orthodontics), nickel-titanium archwire (NiTi, American Orthodontics), elastomeric ligatures (Elastomerics, American Orthodontics))

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fixed metal orthodontic appliance
Description: fixed metal orthodontic appliance (stainless steel brackets (Mini Master MBT 0.022'', American Orthodontics), nickel-titanium archwire (NiTi, American Orthodontics), elastomeric ligatures (Elastomerics, American Orthodontics))

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixed non-metal orthodontic appliance
Description: fixed non-metal orthodontic appliance (ceramic brackets (Radiance MBT 0.022'', American Orthodontics), polyamide thread, elastomeric ligatures (Elastomerics, American Orthodontics))

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: fixed non-metal orthodontic appliance
Description: fixed non-metal orthodontic appliance (ceramic brackets (Radiance MBT 0.022'', American Orthodontics), polyamide thread, elastomeric ligatures (Elastomerics, American Orthodontics))

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oral hygiene
Description: conducting regular oral hygiene, commonly recommended for orthodontic patients (toothbrush + toothpaste with a low fluoride concentration of 1450 ppm (Parodontax, GSK)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: oral hygiene
Description: conducting regular oral hygiene, commonly recommended for orthodontic patients (toothbrush + toothpaste with a low fluoride concentration of 1450 ppm (Parodontax, GSK)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: conducting regular oral hygiene (Parodontay, GSK) + 0.12% chlorhexidine digluconate mouthwash (Curasept ADS 212, Curaden) daily during one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: conducting regular oral hygiene (Parodontay, GSK) + 0.12% chlorhexidine digluconate mouthwash (Curasept ADS 212, Curaden) daily during one month
Study: NCT05247996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization
Description: Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-target Drug Therapy
Description: Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight \< 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunocheckpoint Inhibitor Therapy
Description: Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Intravenous Chemotherapy
Description: GEMOX regimen (gemcitabine 1000mg/m2, oxaliplatin 100mg/m2) is given for systemic intravenous chemotherapy after the exclusion of contraindications for chemotherapy, and the presence of active lesions is assessed by laboratory and imaging examinations after every two courses of treatment. If active lesions remain, repeated systemic intravenous chemotherapy may be performed. The frequency of chemotherapy is determined by the investigator and is given according to the needs of the patient, usually 6 times with an interval of 21-28 days.
Study: NCT06509464

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caloric restricted diet
Description: Caloric restricted diet
Study: NCT05387096

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Definitive multi-faceted intervention consisting of several components
Description: The definitive intervention will consist of the following components: structured history of medication (SHiM), Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) screening for PIMs and PPOs, drug-drug and drug-disease interactions screening, face-to-face consultation with attending hospital physicians to discuss PIMs, PPOs, interactions and other issues, pre-discharge medication review and adjustment, detailed medication adjustment discharge report to patients' general practitioners (GPs), post-discharge follow-up contact with patients' GPs and community pharmacists at 1 week, 1 month and 3-6 months post -discharge. The interventions will be applied by a trained physician or pharmacist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Definitive multi-faceted intervention consisting of several components
Description: The definitive intervention will consist of the following components: structured history of medication (SHiM), Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) screening for PIMs and PPOs, drug-drug and drug-disease interactions screening, face-to-face consultation with attending hospital physicians to discuss PIMs, PPOs, interactions and other issues, pre-discharge medication review and adjustment, detailed medication adjustment discharge report to patients' general practitioners (GPs), post-discharge follow-up contact with patients' GPs and community pharmacists at 1 week, 1 month and 3-6 months post -discharge. The interventions will be applied by a trained physician or pharmacist.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Sham intervention in the form of the modified Medication Adherence Rating Scale (MARS) questionnaire in addition to standard care.
Study: NCT05074121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04875221

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Connectivity-based neurofeedback
Description: Real-time fMRI neurofeedback will be used to non-invasively regulate neural network connectivity patterns associated with symptoms and emotional arousal among patients with PTSD and healthy individuals, with the aim to induce lasting neuronal effects and reduce symptoms.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Connectivity-based neurofeedback
Description: Real-time fMRI neurofeedback will be used to non-invasively regulate neural network connectivity patterns associated with symptoms and emotional arousal among patients with PTSD and healthy individuals, with the aim to induce lasting neuronal effects and reduce symptoms.
Study: NCT05275959

Intervention type: OTHER
Group type: OTHER
Intervention: A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China
Description: Myopia and obesity in children and adolescents have become serious public health problems that endanger public health, especially in China. Unhealthy lifestyle behaviors are environmental drivers of both myopia and obesity. This protocol describes a study to evaluate the effectiveness of 22510SS, that is 2 h of daytime outdoor activities ('2'); Limit screen time to no more than 2 h per day ('2'); Consume at least 5 servings of fruits and vegetables daily ('5'); Attain 1 h of physical activity daily ('1'); Consume 0 sugar-sweetened beverages ('0'); Reasonable sleep duration ('S'); Regular supervision ('S'). A school-based, multifaceted intervention strategy for myopia and obesity prevention, and to assess and explore the implementation of 22510SS with regards to acceptability, feasibility, adoption, usage and maintenance.
Study: NCT05770193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: The position for every patient will be sitting during application of the tape. The diaphragm muscle will be covered with kinesio tape both anteriorly and posteriorly along the subcostal region. Anteriorly, the base point of an I shaped kinesio tape will be applied on xiphoid process with 50_75% tension on the linea Alba and the tails of the tape were applied toward subcostal curvature. Posteriorly, a second I shaped Kinesio Tape will be applied from the back The base point of the tape will be applied on the projection of 12th Thoracic vertebra with 50 _75% tension and the tails will be applied toward the ribs.
Study: NCT05836766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Y-6 sublingual tablets
Description: Take Y-6 sublingual tablets for 28 days continuously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets of Y-6 sublingual tablet
Description: Take Placebo tablets of Y-6 sublingual tablet for 28 days continuously.
Study: NCT05312138

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The treatment will be internally cooled 70 mm double coil and 110 mm round coil, accompanied by a physiotherapist and neurologist. The coil will be placed on the precentral gyrus. Practices will be held, with each session lasting 20 minutes. Cortical excitability will be provided by high frequency (HF) stimulation (5-Hz).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Posterior Tibial Nerve Stimulation
Description: The treatment parameters will be applied with a pulse current time of 200 μsec, a fixed frequency of 10 Hz, a treatment time of 20 minutes, and a current intensity that the patient can tolerate, which will not cause flexion in the big toe or fan movement in the other fingers. Self-adhesive surface electrodes will be used for stimulation. During the treatment, the patient will lie on his back. The negative electrode will be placed 2 cm posterior to the medial malleolus and the positive electrode will be placed 10 cm proximal.
Study: NCT05121311

Intervention type: DIAGNOSTIC_TEST
Intervention: NeoprediX B1 algorithm
Description: Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
Study: NCT05505110

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Seeding
Description: Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the intervention group will have their nasal cavity swabbed with maternal vaginal secretions.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sterile Swab
Description: Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the control group will have their nasal cavity swabbed with a sterile swab.
Study: NCT06479759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108 antibody and sintilimab
Description: Cohort 1 receive LM-108 monoclonal antibody combined with sintilimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108 antibody and sintilimab and chemotherapy
Description: Cohort 2 receive LM-108 monoclonal antibody combined with sintilimab and chemotherapy for 4-6 cycles. LM-108 monoclonal antibody combined with sintilimab will be maintained
Study: NCT04195984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi-thos® valve and transapical delivery system
Description: Transcatheter mitral valve replacement system
Study: NCT06118359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Support Interhospital Transfer Decisions (SITe)
Description: The SITe intervention and implementation toolkit was developed in Aim 1 through stakeholder activities. SITe, an intervention to support interhospital transfer decisions regarding older EGS patients, includes a checklist and script to be utilized by accepting providers during their conversations with referring providers. The investigators and stakeholders also developed a toolkit for implementation with resources to reduce barriers to and support facilitators of utilizing the tools. The toolkit includes: (1) the checklist and script; (2) methods to train accepting providers on the tools including a PowerPoint presentation and demonstration video; and (3) resources to familiarize other parties (transfer center nurses, referring providers, referring hospitals) with the SITe intervention.
Study: NCT05075824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight \>= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight \>= 100 kg). Dosing schedule will be as per Arm Description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
Study: NCT04998123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeizureStop Device
Description: Intersectional Short Pulse (ISP) Stimulation will be performed using SeizureStop Device. The ISP stimulation method proposed in this study is to increase the intensity of stimulation delivered to targeted brain regions, while minimizing the peripheral effects of stimulation. For sham stimulation, no settings will be modified.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SeizureStop Device
Description: Intersectional Short Pulse (ISP) Stimulation will be performed using SeizureStop Device. The ISP stimulation method proposed in this study is to increase the intensity of stimulation delivered to targeted brain regions, while minimizing the peripheral effects of stimulation. For sham stimulation, no settings will be modified.
Study: NCT06283550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: Abrocitinib will be available in 100 mg strength tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abrocitinib 200 mg
Description: Abrocitinib will be available in 100 mg strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Description: Abrocitinib will be available in 100 mg strength tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT05197192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab i.v. infusion:~Cycle 1 Day 1: Obinutuzumab 100 mg i.v.~Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v.~Cycle 1 Day 8: Obinutuzumab 1000 mg i.v.~Cycle 1 Day 15: Obinutuzumab 1000 mg i.v.~Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v.
Study: NCT05166317

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study: NCT06275906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet and moderate intensity physical exercise (outdoor walking).
Description: Mediterranean Diet, based on the different percentage of carbohydrates and lipids, associated with a program of moderate intensity aerobic physical exercise (outdoor walking), in patients with obesity and NAFLD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet and moderate intensity physical exercise (outdoor walking).
Description: Mediterranean Diet, based on the different percentage of carbohydrates and lipids, associated with a program of moderate intensity aerobic physical exercise (outdoor walking), in patients with obesity and NAFLD.
Study: NCT06138132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101 anti-CD19 CAR-T cell therapy
Description: KYV-101 anti-CD19 CAR-T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard lymphodepletion regimen
Description: Standard lymphodepletion regimen
Study: NCT05733000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devimistat
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devimistat
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devimistat
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Receive PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Receive PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Receive PO
Study: NCT05197192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab i.v. infusion:~Cycle 1 Day 1: Obinutuzumab 100 mg i.v.~Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v.~Cycle 1 Day 8: Obinutuzumab 1000 mg i.v.~Cycle 1 Day 15: Obinutuzumab 1000 mg i.v.~Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax p.o.:~Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg)~Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg)~Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg)~Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg)~Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg)~Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax p.o.:~Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg)~Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg)~Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg)~Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg)~Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg)~Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Cycles 15-24: Days 1-28:~100 mg acalabrutinib twice daily p.o. approx. every 12 hrs (corresponding to a total daily dose of 200 mg).
Study: NCT05733000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05179096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: The program consists of a series of awareness practices: the exercises are presented in progression, starting from the awareness of the external environment, then the self-awareness in the environment, the awareness of the body and the five senses, the awareness of the interconnection among the various forms of life and, eventually, meditation exercises that characterize the awareness of the cognitive processes
Study: NCT05798754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Loss of resistance (LOR) technique
Description: The thoracic epidural space will be identified by the loss of resistance (LOR) technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CompuFlo® technology
Description: The thoracic epidural space will be identified by the CompuFlo® technology